PharmaForce International: U.S. Pharmaceutical Companies Move Toward Utilization of Tracking Platforms for Medical Science Liaison Deployment

A recent study indicates that there has been an increase in frequency of organizations utilizing tracking platforms for Medical Science Liaisons (MSLs), previously used for Field Sales.

News provided by

PharmaForce International

Oct 23, 2018, 13:00 ET

READING, Pa., Oct. 23, 2018 /PRNewswire/ -- Research recently published by PharmaForce International (PFI) reports key changes in the functions of MSLs within 12 leading pharmaceutical companies in the United States. This research is outlined in PFI's 2018 MSL Benchmarking Study.

The majority of these companies within the report indicated that they now require MSLs to use various platforms to track standard information such as number of account calls per day, number of interactions, insights collected and other key details.

In addition to standard information, some companies request documentation of their MSLs' field interactions using a free text format. Any face-to-face communications that lead to significant data recorded between MSLs and Key Opinion Leaders (KOLs) can be reviewed by strategy leads or upper management, and utilized accordingly.

Joyce Wedemeyer, Director of Marketing and Sales at PharmaForce International, says it gives pharmaceutical companies a more organized approach to not only track and compare the performance of their MSLs, but to pull noteworthy insights from interactions with KOLs.

"Furthermore, the utilization of tracking platforms for the MSL function can advance sharing of information throughout commercial and medical affair areas. Essentially, it could improve the capability of personnel within the organization to stay connected" says Wedemeyer.

Additional MSL trends captured in this report include insight specific to:

Key changes in the functions of MSLs within leading pharmaceutical companies
Strategic approaches to the MSL function
Consistent increase in "account-based" organizational approaches vs traditional KOL engagement across field medical organizations
Commitment toward Health Economics Outcomes Research (HEOR) field-based personnel
Reduction in the compensation gap between "start-up biotech" and large pharma salaries

For more information on the report mentioned above, or the upcoming EU5 MSL release, please contact Joyce Wedemeyer at [email protected] or by phone at 610-370-2906.

PharmaForce International (PFI) is a competitive intelligence firm with over two decades of experience in the pharmaceutical and biotech industries. PFI has become the market leader in commercial operations benchmarking and competitive intelligence. The globally focused company employs market place experts uniquely qualified to perform research required by clients in most major pharmaceutical markets around the world.

Related Links https://www.pharmaforce.biz

SOURCE PharmaForce International